MedPage Today on MSN1d
Alzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension StudyBiomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback